Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EXEL Exelixis Inc
- Stocks
- Healthcare
- NASDAQ: EXEL
Price (delayed)
$43.67
Market cap
$11.91B
P/E Ratio
19.41
Dividend/share
N/A
EPS
$2.25
Enterprise value
$11.91B
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work
Highlights
The gross profit has grown by 26% YoY and by 6% from the previous quarter
The company's EPS rose by 25% QoQ
The P/E is 48% below the 5-year quarterly average of 37.5 but 10% above the last 4 quarters average of 17.6
The company's equity fell by 5% QoQ
EXEL's quick ratio is down by 3.5% since the previous quarter
Key stats
What are the main financial stats of EXEL
Market
Valuations
Earnings
Shares outstanding
272.71M
Market cap
$11.91B
Enterprise value
$11.91B
Price to earnings (P/E)
19.41
Price to book (P/B)
5.74
Price to sales (P/S)
5.3
EV/EBIT
14.21
EV/EBITDA
13.32
EV/Sales
5.18
Revenue
$2.3B
Gross profit
$2.22B
Operating income
$762.01M
Net income
$643.57M
EBIT
$838.06M
EBITDA
$894.63M
Free cash flow
$820.89M
Per share
Balance sheet
Liquidity
EPS
$2.25
EPS diluted
$2.2
Free cash flow per share
$2.94
Book value per share
$7.61
Revenue per share
$8.25
TBVPS
$9.95
Total assets
$2.84B
Total liabilities
$706.22M
Debt
$187.13M
Equity
$2.13B
Working capital
$997.4M
Debt to equity
0.09
Current ratio
3.5
Quick ratio
3.29
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
38.9%
Gross margin
96.8%
Net margin
28%
Operating margin
33.1%
Return on assets
22.3%
Return on equity
29.4%
Return on invested capital
34.8%
Return on capital employed
34.4%
Return on sales
36.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXEL stock price
How has the Exelixis stock price performed over time
Intraday
1.35%
1 week
8.17%
1 month
1.35%
1 year
93.83%
YTD
31.14%
QTD
18.28%
Financial performance
How have Exelixis's revenue and profit performed over time
Revenue
$2.3B
Gross profit
$2.22B
Operating income
$762.01M
Net income
$643.57M
Gross margin
96.8%
Net margin
28%
The net margin has soared by 152% YoY and by 17% from the previous quarter
The gross profit has grown by 26% YoY and by 6% from the previous quarter
Exelixis's operating income has increased by 26% QoQ
The revenue has grown by 24% YoY and by 6% from the previous quarter
Price vs fundamentals
How does EXEL's price correlate with its fundamentals
Growth
What is Exelixis's growth rate over time
Valuation
What is Exelixis stock price valuation
P/E
19.41
P/B
5.74
P/S
5.3
EV/EBIT
14.21
EV/EBITDA
13.32
EV/Sales
5.18
The P/E is 48% below the 5-year quarterly average of 37.5 but 10% above the last 4 quarters average of 17.6
The company's EPS rose by 25% QoQ
EXEL's P/B is 79% above its 5-year quarterly average of 3.2 and 47% above its last 4 quarters average of 3.9
The company's equity fell by 5% QoQ
EXEL's price to sales (P/S) is 36% higher than its last 4 quarters average of 3.9 and 15% higher than its 5-year quarterly average of 4.6
The revenue has grown by 24% YoY and by 6% from the previous quarter
Efficiency
How efficient is Exelixis business performance
The company's return on sales has surged by 161% YoY and by 16% QoQ
The company's return on equity rose by 24% QoQ
The ROA has grown by 23% from the previous quarter
The ROIC has grown by 22% from the previous quarter
Dividends
What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXEL.
Financial health
How did Exelixis financials performed over time
EXEL's total liabilities is up by 4.5% year-on-year
EXEL's current ratio is down by 3.6% since the previous quarter
The debt is 91% less than the equity
The debt has decreased by 7% YoY
The company's equity fell by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.